logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics given access to genetic database in its bid to find new breakthrough treatments

Genomics England has whole sequencing data on 100,000 genomes

1559025309_genome.jpg
Code to life: a genome is an organism’s complete set of DNA, including all of its genes

Silence Therapeutics PLC (LON:SLN) has been given access to part of a genetic database as it bids to find treatments for rare diseases and ailments.

Genomics England has whole sequencing data on 100,000 genomes.

A genome is an organism’s complete set of DNA, including all of its genes. Each genome contains the information needed to build and maintain that organism.

It is the key to understanding how people differ genetically and therefore how they might respond to different medicines.

Data mining exercise 

In the case of Silence, an expert in silencing disease-associated genes, having access to the database will help in its drug development effort.

Under the terms of the deal with Genomics England, Silence will “data mine” a subset of the information to focus on rare diseases and cardio-metabolic illnesses.

It wants to find disease-modifying target genes best suited to its unique technology.

The exercise should also help with “patient stratification” (dividing them into groups and sub-groups) and recruitment as the company develops its RNAi product candidates.

“This key collaboration will help us increase innovation in our target gene choices and will also be attractive to potential partners as we explore a variety of business development opportunities," said Silence chief executive, Dr David Horn Solomon.

Quick facts: Silence Therapeutics PLC

Price: 386 GBX

AIM:SLN
Market: AIM
Market Cap: £302.39 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Silence Therapeutics 'charging ahead with its key...

David Solomon, chief executive of Silence Therapeutics PLC (LON:SLN), updates on developments across their three key programmes - SLN 500, 124 and 360. Discussing the firm's current valuation, Solomon says ''there's a lot more steam in the engine''. ''I think that's what's exciting - we're...

2 weeks, 3 days ago

2 min read